COCP vs. TNXP, VAXX, TRAW, TLPH, AYTU, VBIV, EDSA, NERV, HUGE, and VINC
Should you be buying Cocrystal Pharma stock or one of its competitors? The main competitors of Cocrystal Pharma include Tonix Pharmaceuticals (TNXP), Vaxxinity (VAXX), Traws Pharma (TRAW), Talphera (TLPH), Aytu BioPharma (AYTU), VBI Vaccines (VBIV), Edesa Biotech (EDSA), Minerva Neurosciences (NERV), FSD Pharma (HUGE), and Vincerx Pharma (VINC). These companies are all part of the "pharmaceutical preparations" industry.
Tonix Pharmaceuticals (NASDAQ:TNXP) and Cocrystal Pharma (NASDAQ:COCP) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, profitability, dividends, analyst recommendations, risk, media sentiment, community ranking and valuation.
Cocrystal Pharma has lower revenue, but higher earnings than Tonix Pharmaceuticals. Cocrystal Pharma is trading at a lower price-to-earnings ratio than Tonix Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
In the previous week, Cocrystal Pharma had 2 more articles in the media than Tonix Pharmaceuticals. MarketBeat recorded 3 mentions for Cocrystal Pharma and 1 mentions for Tonix Pharmaceuticals. Cocrystal Pharma's average media sentiment score of 0.93 beat Tonix Pharmaceuticals' score of 0.92 indicating that Tonix Pharmaceuticals is being referred to more favorably in the media.
82.3% of Tonix Pharmaceuticals shares are owned by institutional investors. Comparatively, 6.7% of Cocrystal Pharma shares are owned by institutional investors. 0.5% of Tonix Pharmaceuticals shares are owned by insiders. Comparatively, 25.1% of Cocrystal Pharma shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Tonix Pharmaceuticals currently has a consensus price target of $5.50, indicating a potential upside of 3,103.26%. Cocrystal Pharma has a consensus price target of $10.00, indicating a potential upside of 478.30%. Given Cocrystal Pharma's higher probable upside, analysts clearly believe Tonix Pharmaceuticals is more favorable than Cocrystal Pharma.
Tonix Pharmaceuticals received 318 more outperform votes than Cocrystal Pharma when rated by MarketBeat users. However, 75.00% of users gave Cocrystal Pharma an outperform vote while only 63.96% of users gave Tonix Pharmaceuticals an outperform vote.
Tonix Pharmaceuticals has a beta of 2.16, indicating that its stock price is 116% more volatile than the S&P 500. Comparatively, Cocrystal Pharma has a beta of 1.3, indicating that its stock price is 30% more volatile than the S&P 500.
Tonix Pharmaceuticals' return on equity of -59.62% beat Cocrystal Pharma's return on equity.
Summary
Tonix Pharmaceuticals beats Cocrystal Pharma on 8 of the 15 factors compared between the two stocks.
Get Cocrystal Pharma News Delivered to You Automatically
Sign up to receive the latest news and ratings for COCP and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding COCP and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Cocrystal Pharma Competitors List
Related Companies and Tools
